Tatva Chintan Pharma Chem Limited was formerly incorporated as `Tatva Chintan Pharma Chem Private Limited` on 12 June 1996. The company's status converted from Private Limited into a Public Limited Company effective from 27 January 2021, and its name also changed from `Tatva Chintan Pharma Chem Private Limited` to `Tatva Chintan Pharma Chem Limited`. The Company is promoted by Mr. Chintan Nitin Kumar Shah, Mr. Ajay Kumar Mansukhlal Patel, and Mr. Shekhar Rasiklal Somani.
The Company is a globally recognized specialty chemical player with several market-leading products in its portfolio. Tatva Chintan Pharma Chem Limited is an India-based specialty chemical manufacturing company engaged in the manufacturing of a variety of chemicals including structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts for capacitor batteries, and pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC).
The company operates through a diversified product portfolio serving multiple industries. Its SDAs are quaternary salts, which help in the formation of channels and pores during the synthesis of zeolites. Its PTCs are used to facilitate the migration of a reactant from one phase into another phase where the reaction occurs in a heterogeneous multi-phase system.
The Company operates two manufacturing facilities situated at Ankleshwar and Dahej in Bharuch, Gujarat, India. The Company is focused on serving various customers across diverse industries, including the automotive, petroleum, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care, and flavors and fragrances industries.
In 2004, the company obtained a license from the FDA Gujarat for the Ankleshwar manufacturing plant. It also boasts a modern analytical development laboratory and an R&D center approved by the Department of Scientific and Industrial Research.
The company's financial performance in FY25 showed a decline in profitability despite some quarterly sales growth.
For the full year ended March 2025, net profit declined 81.19% to ₹5.71 crore compared to ₹30.35 crore in the previous year (FY24). Sales also declined 2.74% to ₹382.71 crore in FY25 from ₹393.50 crore in FY24.
For the quarter ended March 2025 (Q4 FY25), Net profit of Tatva Chintan Pharma Chem declined 89.28% to ₹1.03 crore compared to ₹9.61 crore in the previous quarter (Q4 FY224). Sales, however, rose 9.76% to ₹107.86 crore in Q4 FY25 from ₹98.27 crore in Q4 FY24.
• Revenue (FY25): ₹382.71 crore
• Net Profit (FY25): ₹5.71 crore
• Quarterly Revenue (Q4 FY25): ₹107.86 crore
• Quarterly Net Profit (Q4 FY25): ₹1.03 crore
• Market Capitalization: ₹2,333.12 crore (as of July 3, 2025)
• Promoter Holding: 72.0%
• P/E Ratio: 408.60
As of July 3, 2025, the market capitalization of Tatva Chintan Pharma Chem Ltd (TATVA) stands at ₹2,333.12 crore. The company is almost debt-free, which is a significant positive for its financial stability.
The 52-week high for TATVA is ₹1199.95, and the 52-week low is ₹621. The P/E (price-to-earnings) ratio of Tatva Chintan Pharma Chem Ltd (TATVA) is 408.60, indicating a high valuation relative to its earnings.
In the fourth quarter of FY2025, the company reported a revenue growth of 10% year-on-year. However, it faced operational challenges amid a tough macroeconomic environment, reflected in a significant 43% decline in EBITDA. While segments like Phase Transfer Catalysts and Structure-Directing Agents showed promising demand, the Electrolyte Salts segment faced setbacks, indicating mixed market sentiment.
Strategic adjustments are underway, including a focus on high-purity materials and the agrochemical sector, where growth projections range from 40% to 70%. Despite fluctuations in raw material prices and operational inefficiencies, management remains optimistic about future profitability, driven by new product commercialization and enhanced customer engagement.
CRISIL recently downgraded Tatva Chintan's ratings to BBB+/Stable and A2 due to business risk moderation. The company has maintained transparency with regular updates to stakeholders and has been addressing market queries regarding stock price movements.
Tatva Chintan Pharma Chem has been maintaining a healthy dividend payout of 22.0%. The anticipated recovery in demand, particularly in the hybrid vehicle battery sector, further supports a positive outlook for the upcoming fiscal year.
The company continues to focus on innovation and expansion in its core business segments while navigating the challenging market conditions in the specialty chemicals industry, aiming for long-term growth and sustained market presence.
